Skip to main content
    E

    Ernexa Therapeutics Inc. (ERNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.65
    -0.03 (-1.79%)

    Market Cap: $2.84M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Ernexa Therapeutics Inc. (ERNA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 6, 2026. Financial statements from company filings, amounts in US dollars.

    Ernexa Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025, down 100.0% from the year before. That year, net income was -$14.08M, operating cash flow was -$7.02M and free cash flow was -$7.05M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$2.94M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $9.32M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0-100.0%N/AN/AN/A
    Dec 2024$582.00K+755.9%83.5%-2693.1%-7652.7%
    Dec 2023$68.00KN/A-247.1%-31080.9%-31864.7%
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0-100.0%N/AN/AN/A
    Dec 2019$19.81M-15.1%100.0%-8.9%-10.3%
    Dec 2018$23.34M+9.7%100.0%0.9%-1.1%
    Dec 2017$21.27M-4.7%100.0%-6.6%-5.1%
    Dec 2016$22.31MN/A100.0%-10.2%-13.1%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$582.00K$68.00K$0$0$0$19.81M$23.34M$21.27M$22.31M
    Cost of revenue$0$96.00K$236.00K$0$0$0$0$0$0$0
    Gross profit$0$486.00K-$168.00K$0$0$0$19.81M$23.34M$21.27M$22.31M
    Research and development$4.16M$4.60M$6.38M$10.39M$93.24M$3.95M$0$0$0$0
    Operating income-$9.32M-$15.67M-$21.14M-$33.22M-$113.73M-$7.25M-$1.76M$203.00K-$1.40M-$2.28M
    Net income-$14.08M-$44.54M-$21.67M-$24.58M-$122.55M-$7.29M-$2.05M-$259.00K-$1.08M-$2.92M
    EBITDAN/A-$8.67M-$19.77M-$24.01MN/A-$7.24M$1.41M$2.89M$1.86M$614.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$1.00K$487.00K$47.00K$47.00K$17.00K
    Gross profit$0$0$0-$69.00K$0$0$0$1.00K$547.00K-$48.00K-$14.00K-$49.00K
    Operating income-$2.99M-$4.10M-$5.59M-$2.10M-$1.99M-$2.50M-$2.73M-$2.70M-$2.26M-$4.93M-$5.79M-$5.76M
    Net income-$2.94M-$4.01M-$5.51M-$1.50M-$1.24M-$3.14M-$8.20M-$5.76M-$26.60M-$5.53M-$6.65M-$6.15M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $41.00K by $1.84M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$5.83M$5.27M$49.13M$22.28M$31.52M$12.91M$14.13M$14.86M$16.57M$16.70M
    Current assets$3.13M$2.35M$9.60M$13.68M$18.77M$1.73M$6.07M$6.79M$9.64M$10.66M
    Cash and equivalents$1.88M$1.73M$7.58M$11.45M$16.98M$1.63M$3.21M$2.54M$3.38M$5.69M
    Total liabilities$3.43M$3.57M$46.90M$10.17M$6.02M$5.25M$9.03M$7.95M$11.03M$12.63M
    Short-term debt$41.00K$0$2.22M$2.04M$426.00K$410.00K$2.74M$1.04M$5.24M$3.14M
    Long-term debtN/AN/A$6.77M$0N/A$194.00K$0$2.73M$8.00K$5.12M
    Shareholder equity$2.40M$1.70M$2.23M$12.11M$25.50M$7.66M$5.09M$6.92M$5.54M$4.07M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$7.10M$6.32M$10.54M$5.83M$6.17M$7.58M$5.06M$5.27M$7.72M$46.49M$49.66M$49.13M
    Total liabilities$2.75M$3.12M$3.68M$3.43M$2.60M$3.14M$11.01M$3.57M$53.11M$55.01M$53.07M$46.90M
    Cash and equivalents$5.58M$5.03M$9.18M$1.88M$3.05M$4.32M$1.92M$1.73M$4.26M$2.59M$5.12M$7.58M
    Shareholder equity$4.35M$3.20M$6.86M$2.40M$3.57M$4.44M-$5.95M$1.70M-$45.39M-$8.53M-$3.41M$2.23M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$7.02M-$15.84M-$20.41M-$20.98M-$23.49M-$8.10M$2.74M$1.36M$549.00K$23.00K
    Capital expenditures$37.00K$369.00K$19.00K$297.00K$154.00K$39.00K$966.00K$1.61M$1.45M$840.00K
    Free cash flow-$7.05M-$16.20M-$20.43M-$21.27M-$23.64M-$8.14M$1.78M-$247.00K-$903.00K-$817.00K
    Dividends paidN/A$16.00K$16.00K$16.00K$8.00K$0$16.00K$16.00K$16.00K$16.00K
    Share repurchases$0$34.00K$0$0N/AN/AN/AN/AN/AN/A
    Investing cash flow-$37.00K-$365.00K-$19.00K-$47.00K-$22.74M-$39.00K-$1.06M-$1.58M-$1.45M-$840.00K
    Financing cash flow$7.21M$6.26M$16.56M$19.58M$61.59M$4.67M-$1.10M-$303.00K-$1.47M$3.26M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$3.17M-$4.15M-$2.26M-$1.15M-$1.27M-$2.53M-$2.06M-$3.54M-$6.29M-$2.26M-$3.75M-$4.66M
    Capital expendituresN/A$3.00K$2.00K$15.00K$22.00K$0$0$0$19.00K$249.00K$101.00K$19.00K
    Free cash flowN/A-$4.16M-$2.27M-$1.16M-$1.29M-$2.53M-$2.06M-$3.54M-$6.30M-$2.51M-$3.85M-$4.68M
    Last 12 quarters

    Frequently Asked Questions About ERNA

    What is Ernexa Therapeutics' annual revenue?

    Ernexa Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    How fast is Ernexa Therapeutics' revenue growing?

    Revenue was down 100.0% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Ernexa Therapeutics profitable?

    No. Ernexa Therapeutics reported net income of -$14.08M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does ERNA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$7.02M minus capital expenditures of $37.00K produced free cash flow of -$7.05M.

    How much debt does Ernexa Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $41.00K and cash and equivalents of $1.88M.